Home / Advanced Search

  • Title/Keywords

  • Author/Affliations

  • Journal

  • Article Type

  • Start Year

  • End Year

Update SearchingClear
  • Articles
  • Online
Search Results (2)
  • Open Access

    ARTICLE

    Neoadjuvant intermediate-course versus long-course chemoradiotherapy in T3-4/N0+ rectal cancer: Istanbul R-02 phase II randomized study

    SUKRAN SENYUREK1, SEZER SAGLAM2,*, ESRA KAYTAN SAGLAM3, HAKAN YANAR4, KAAN GOK4, DIDEM TASTEKIN5, CANAN KOKSAL AKBAS6, NERGIZ DAGOGLU SAKIN3, GULBIZ DAGOGLU KARTAL7, EMRE BALIK8, METIN KESKIN4, YASEMIN SANLI9, MINE GULLUOGLU10, ZULEYHA AKGUN11

    Oncology Research, Vol.31, No.5, pp. 689-696, 2023, DOI:10.32604/or.2023.030351

    Abstract Radiation therapy (RT) is typically applied using one of two standard approaches for preoperative treatment of resectable locally advanced rectal cancer (LARC): short-course RT (SC-RT) alone or long-course RT (LC-RT) with concurrent fluorouracil (5-FU) chemotherapy. The Phase II single-arm KROG 11-02 study using intermediate-course (IC) (33 Gy (Gray)/10 fr (fraction) with concurrent capecitabine) preoperative chemoradiotherapy (CRT) demonstrated a pathologically complete response rate and a sphincter-sparing rate that were close to those of LC-CRT. The current trial aim to compare the pathological/oncological outcomes, toxicity, and quality of life results of LC-CRT and IC-CRT in cases of… More >

  • Open Access

    ARTICLE

    Effects of the number of neoadjuvant therapy cycles on clinical outcomes, safety, and survival in patients with metastatic colorectal cancer undergoing metastasectomy

    YUNG-SUNG YEH1,2,3, HSIANG-LIN TSAI4,5, YEN-CHENG CHEN4,6, WEI-CHIH SU4,6, PO-JUNG CHEN4,6, TSUNG-KUN CHANG4,6,7, CHING-CHUN LI4, CHING-WEN HUANG4,5, JAW-YUAN WANG4,5,6,8,9,10,*

    Oncology Research, Vol.30, No.2, pp. 65-76, 2022, DOI:10.32604/or.2022.026659

    Abstract The controversial outcomes in patients with metastatic colorectal cancer (mCRC) highlight the need for developing effective systemic neoadjuvant treatment strategies to improve clinical results. The optimal treatment cycles in patients with mCRC for metastasectomy remain undefined. This retrospective study compared the efficacy, safety, and survival of cycles of neoadjuvant chemotherapy/targeted therapy for such patients. Sixty-four patients with mCRC who received neoadjuvant chemotherapy/targeted therapy following metastasectomy were enrolled between January 2018 and April 2022. Twenty-eight patients received 6 cycles of chemotherapy/targeted therapy, whereas 36 patients received ≥7 cycles (median, 13; range, 7–20). Clinical outcomes, including response,… More >

Displaying 1-10 on page 1 of 2. Per Page